Back to all companies
Sign in
Back to all companies
Keylika logo

Keylika

Summer 2022Active

Redefining the Standard of Care for Iron Deficiency Anemia

Save
Keylika logo

Keylika

Summer 2022Active

Redefining the Standard of Care for Iron Deficiency Anemia

Save
Company details

Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes.

Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.

Location
San Francisco, CA, USA; Walnut Creek, CA, USA
Founded
Unknown
Category
AI-powered Drug Discovery
YC Directory Pagewww.keylika.com
Founders
  • BC
    Buddha Chaudhuri
    Founder
    X / TwitterLinkedIn
  • FC
    Frederik Ceyssens
    Founder
    LinkedIn

Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes.

Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.

Location
San Francisco, CA, USA; Walnut Creek, CA, USA
Founded
Unknown
Category
AI-powered Drug Discovery
YC Directory Pagewww.keylika.com
Founders
  • BC
    Buddha Chaudhuri
    Founder
    X / TwitterLinkedIn
  • FC
    Frederik Ceyssens
    Founder
    LinkedIn
Pro

Upgrade to Pro, then request the Keylika teardown.

This company does not have a completed analysis yet. Choose a Pro plan first, then use one of your 5 monthly research requests to have our agent investigate Keylika. The full teardown, rebuild plan, and technical specs unlock when it lands.

  • Use Pro to request the first Keylika teardown and keep the finished report in your account.
  • Read every completed teardown and rebuild plan already in the database.
  • Unlock implementation-ready technical specs and 5 fresh research requests each month.

Choose your Pro plan

$20/ month

Find one worth rebuilding, get the teardown, open the implementation-ready specs, and use fresh report requests when you want deeper research.

See Pro plans
Full teardown library
Specs for every company
5 fresh requests / month
CLI for agent imports
Startups.RIP — Dead startups, alive ideas
PricingContactPrivacyGot feedback? DM @oscrhong